BidaskClub lowered shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research report sent to investors on Tuesday.
A number of other brokerages have also issued reports on KURA. Wedbush began coverage on Kura Oncology in a research report on Tuesday, December 26th. They set a buy rating and a $19.00 target price on the stock. Oppenheimer set a $18.00 target price on Kura Oncology and gave the stock a buy rating in a research report on Thursday, November 16th. ValuEngine lowered Kura Oncology from a hold rating to a sell rating in a research report on Friday, December 1st. Zacks Investment Research lowered Kura Oncology from a buy rating to a hold rating in a research report on Friday, September 29th. Finally, Cann reaffirmed a buy rating and set a $17.50 target price on shares of Kura Oncology in a research report on Monday, December 11th. Three analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $18.08.
Shares of Kura Oncology (NASDAQ KURA) traded up $0.40 during trading on Tuesday, hitting $16.05. The stock had a trading volume of 133,729 shares, compared to its average volume of 179,598. The firm has a market capitalization of $472.87, a price-to-earnings ratio of -10.35 and a beta of 4.89. The company has a quick ratio of 13.48, a current ratio of 13.48 and a debt-to-equity ratio of 0.07. Kura Oncology has a 12 month low of $5.78 and a 12 month high of $17.50.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). equities analysts anticipate that Kura Oncology will post -1.52 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of KURA. Candriam Luxembourg S.C.A. acquired a new position in Kura Oncology during the third quarter valued at $8,073,000. EAM Investors LLC acquired a new position in Kura Oncology during the third quarter valued at $2,884,000. State Street Corp acquired a new position in Kura Oncology during the second quarter valued at $1,394,000. Northern Trust Corp raised its position in Kura Oncology by 939.3% during the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock valued at $1,372,000 after buying an additional 133,293 shares during the period. Finally, Artal Group S.A. acquired a new position in Kura Oncology during the third quarter valued at $1,495,000. 64.26% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/bidaskclub-lowers-kura-oncology-kura-to-sell.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.